$ASPI
ASP Isotopes Inc. Stock $aspi

$aspi Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000147793224001964 Filed on April 10, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023
Revenue	$1.022M	$433.0K	$433.0K
YoY Change
Cost Of Revenue	$601.3K	$294.1K	$294.1K
YoY Change
Gross Profit	$421.0K	$139.0K	$139.0K
YoY Change
Gross Profit Margin	41.18%	32.09%	32.09%
Selling, General & Admin	$7.405M	$4.097M	$15.42M
YoY Change	80.85%	197.43%	302.99%
% of Gross Profit	1758.85%	2948.06%	11093.32%
Research & Development	$473.3K	$65.17K	$764.6K
YoY Change	87.16%	-30.99%	-39.96%
% of Gross Profit	112.42%	46.9%	550.18%
Depreciation & Amortization	$146.5K	$37.43K	$37.43K
YoY Change	87624.55%
% of Gross Profit	34.8%	26.93%	26.93%
Operating Expenses	$7.878M	$4.162M	$16.18M
YoY Change	81.22%	182.78%	217.33%
Operating Profit	-$7.457M	-$4.023M	-$16.04M
YoY Change	71.53%		214.61%
Interest Expense	$69.08K	-$67.73K	-$63.72K
YoY Change	6179.82%	-4676.35%	-1985.21%
% of Operating Profit
Other Income/Expense, Net	-$1.410M	-$85.50K	-$194.5K
YoY Change	-2404.35%	-151.43%	-226.4%
Pretax Income	-$8.868M	-$4.176M	-$16.30M
YoY Change	106.88%	220.24%	229.62%
Income Tax	$13.77K	-$6.130K	-$6.130K
% Of Pretax Income
Net Earnings	-$8.881M	-$4.162M	-$16.29M
YoY Change	107.2%	219.16%	229.34%
Net Earnings / Revenue	-868.77%	-961.21%	-3760.99%
Basic Earnings Per Share	-$0.24		-$0.49
Diluted Earnings Per Share	-$0.24	-$0.10	-$0.49
COMMON SHARES
Basic Shares Outstanding	48.92M shares	48.77M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q2	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$28.26M	$7.908M	$7.908M
YoY Change	679.4%	231.01%	231.01%
Cash & Equivalents	$28.26M	$7.908M
Short-Term Investments
Other Short-Term Assets	$3.293M	$1.664M	$1.664M
YoY Change	714.46%	82.26%	82.26%
Inventory		$0.00
Prepaid Expenses
Receivables	$515.5K	$216.5K	$216.5K
Other Receivables	$0.00	$721.6K	$721.6K
Total Short-Term Assets	$32.07M	$10.51M	$10.51M
YoY Change	695.71%	218.29%	218.29%
LONG-TERM ASSETS
Property, Plant & Equipment	$17.77M	$11.97M	$11.97M
YoY Change	129.79%	45.98%	32.22%
Goodwill	$3.289M	$3.267M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$208.4K	$1.793M	$1.793M
YoY Change	-39.19%	1184.06%	1184.02%
Total Long-Term Assets	$22.69M	$17.03M	$17.03M
YoY Change	160.2%	85.25%	85.25%
TOTAL ASSETS
Total Short-Term Assets	$32.07M	$10.51M	$10.51M
Total Long-Term Assets	$22.69M	$17.03M	$17.03M
Total Assets	$54.76M	$27.54M	$27.54M
YoY Change	329.47%	120.4%	120.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.433M	$1.112M	$1.112M
YoY Change	263.08%	-17.94%	-17.94%
Accrued Expenses	$2.456M	$1.648M	$1.648M
YoY Change	204.04%	356.15%	304.72%
Deferred Revenue
YoY Change
Short-Term Debt	$31.61K	$470.4K	$470.4K
YoY Change	-6.62%	1289.66%	1289.66%
Long-Term Debt Due	$120.6K	$61.94K	$61.94K
YoY Change
Total Short-Term Liabilities	$8.011M	$5.674M	$5.674M
YoY Change	311.05%	193.02%	193.02%
LONG-TERM LIABILITIES
Long-Term Debt	$29.65M	$207.1K	$207.1K
YoY Change
Other Long-Term Liabilities	$1.653M	$2.720M	$2.720M
YoY Change	155.02%	266.31%	266.31%
Total Long-Term Liabilities	$1.653M	$2.927M	$2.927M
YoY Change	155.02%	294.21%	294.21%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.011M	$5.674M	$5.674M
Total Long-Term Liabilities	$1.653M	$2.927M	$2.927M
Total Liabilities	$40.40M	$11.25M	$11.25M
YoY Change	1455.55%	319.81%	319.81%
SHAREHOLDERS EQUITY
Retained Earnings	-$39.72M	-$23.84M
YoY Change	157.01%	215.62%
Common Stock	$521.3K	$489.2K
YoY Change	39.45%	36.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$11.01M	$16.30M	$16.30M
YoY Change
Total Liabilities & Shareholders Equity	$54.76M	$27.54M	$27.54M
YoY Change	329.47%	120.4%	120.4%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$8.881M	-$4.162M	-$16.29M
YoY Change	107.2%	219.16%	229.34%
Depreciation, Depletion And Amortization	$146.5K	$37.43K	$37.43K
YoY Change	87624.55%
Cash From Operating Activities	-$5.125M	-$2.052M	-$5.412M
YoY Change	307.73%	138.09%	84.1%
INVESTING ACTIVITIES
Capital Expenditures	$2.622M	$1.141M	$2.331M
YoY Change	1689.2%	26.46%	-47.88%
Acquisitions
YoY Change
Other Investing Activities		-$121.9K	-$121.9K
YoY Change
Cash From Investing Activities	-$2.622M	-$1.263M	-$2.453M
YoY Change	1689.2%	39.96%	-45.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$14.13M
YoY Change			74.01%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	12.15M	8.895M	13.39M
YoY Change		134.68%	101.56%
NET CHANGE
Cash From Operating Activities	-5.125M	-2.052M	-5.412M
Cash From Investing Activities	-2.622M	-1.263M	-2.453M
Cash From Financing Activities	12.15M	8.895M	13.39M
Net Change In Cash	4.404M	5.580M	5.520M
YoY Change	-413.8%	175.42%	-815.01%
FREE CASH FLOW
Cash From Operating Activities	-$5.125M	-$2.052M	-$5.412M
Capital Expenditures	$2.622M	$1.141M	$2.331M
Free Cash Flow	-$7.747M	-$3.194M	-$7.744M
YoY Change	451.98%	80.99%	4.46%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001921865
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35907127	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48923276	shares
CY2023Q4	us-gaap	Business Combination Acquisition Of Less Than100 Percent Noncontrolling Interest Fair Value BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue	1821021	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023	aspi	Weighted Average Remaining Contractual Term In Years Beginning WeightedAverageRemainingContractualTermInYearsBeginning	P9Y4M24D
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39069
CY2023	dei	Entity Registrant Name EntityRegistrantName	ASP Isotopes Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-2618235
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	1101 Pennsylvania Avenue NW
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Washington
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	DC
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20004
CY2023	dei	City Area Code CityAreaCode	202
CY2023	dei	Local Phone Number LocalPhoneNumber	756-2245
CY2023	dei	Security12b Title Security12bTitle	Common stock, par value $0.01 per share
CY2023	dei	Trading Symbol TradingSymbol	ASPI
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Public Float EntityPublicFloat	119200000	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48923276	shares
CY2023	dei	Auditor Firm AuditorFirmId	274
CY2023	dei	Auditor Name AuditorName	EISNERAMPER LLP
CY2023	dei	Auditor Location AuditorLocation	Iselin, New Jersey
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7908181	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2389140	usd
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	216504	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	0	usd
CY2023Q4	aspi	Receivable From Noncontrolling Interests Current ReceivableFromNoncontrollingInterestsCurrent	721548	usd
CY2022Q4	aspi	Receivable From Noncontrolling Interests Current ReceivableFromNoncontrollingInterestsCurrent	0	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1664023	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	913005	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	10510256	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	3302145	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10712839	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8200595	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1258701	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	853889	usd
CY2023Q4	us-gaap	Goodwill Goodwill	3267103	usd
CY2022Q4	us-gaap	Goodwill Goodwill	0	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1793014	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	139636	usd
CY2023Q4	us-gaap	Assets Assets	27541913	usd
CY2022Q4	us-gaap	Assets Assets	12496265	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1111819	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1354903	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1311245	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	361246	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	470396	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	33854	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	61941	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	0	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	336564	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	45903	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	882000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	0	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1500000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	0	usd
CY2023Q4	aspi	Fair Value Of Shares Issuable FairValueOfSharesIssuable	0	usd
CY2022Q4	aspi	Fair Value Of Shares Issuable FairValueOfSharesIssuable	140455	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5673965	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1936361	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	110578	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	0	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	207092	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1066647	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	742443	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1653000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	usd
CY2023Q4	us-gaap	Liabilities Liabilities	8711282	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2678804	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48923276	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35907127	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	489233	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	359071	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	40567003	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	16756426	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23839300	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7553066	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-920982	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	255030	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	16295954	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	9817461	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	2534677	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	0	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	18830631	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9817461	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27541913	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12496265	usd
CY2023	us-gaap	Revenues Revenues	433026	usd
CY2022	us-gaap	Revenues Revenues	0	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	294056	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	usd
CY2023	us-gaap	Gross Profit GrossProfit	138970	usd
CY2022	us-gaap	Gross Profit GrossProfit	0	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	764581	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1273536	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15416388	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3825512	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	16180969	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	5099048	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-16041999	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-5099048	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	45753	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	0	usd
CY2023	aspi	Change In Fair Value Of Share Liability ChangeInFairValueOfShareLiability	-194540	usd
CY2022	aspi	Change In Fair Value Of Share Liability ChangeInFairValueOfShareLiability	150527	usd
CY2023	us-gaap	Interest Income Other InterestIncomeOther	9074	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	3382	usd
CY2023	us-gaap	Interest Expense InterestExpense	118547	usd
CY2022	us-gaap	Interest Expense InterestExpense	0	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-258260	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	153909	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16300259	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4945139	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-6133	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-16294126	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-4945139	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-7892	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	usd
CY2023	aspi	Net Income Loss Attributable To Asp Isotopes Inc Shareholders NetIncomeLossAttributableToAspIsotopesIncShareholders	-16286234	usd
CY2022	aspi	Net Income Loss Attributable To Asp Isotopes Inc Shareholders NetIncomeLossAttributableToAspIsotopesIncShareholders	-4945139	usd
CY2023	aspi	Net Loss Per Share Attributable To Asp Isotopes Inc Shareholders Basic And Diluted NetLossPerShareAttributableToAspIsotopesIncShareholdersBasicAndDiluted	-0.49
CY2022	aspi	Net Loss Per Share Attributable To Asp Isotopes Inc Shareholders Basic And Diluted NetLossPerShareAttributableToAspIsotopesIncShareholdersBasicAndDiluted	-0.18
CY2023	aspi	Weighted Average Shares Of Common Stock Outstanding Basic And Diluted WeightedAverageSharesOfCommonStockOutstandingBasicAndDiluted	33066708	shares
CY2022	aspi	Weighted Average Shares Of Common Stock Outstanding Basic And Diluted WeightedAverageSharesOfCommonStockOutstandingBasicAndDiluted	26793748	shares
CY2023	us-gaap	Profit Loss ProfitLoss	-16294126	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-4945139	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	-1176012	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	236307	usd
CY2023	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest	-17470138	usd
CY2022	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest	-4708832	usd
CY2023	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	27255	usd
CY2022	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	0	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-17497393	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-4708832	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5997664	usd
CY2022	aspi	Issuance Of Common Stock Net Of Issuance Costs Amount IssuanceOfCommonStockNetOfIssuanceCostsAmount	2738812	usd
CY2022	aspi	Issuance Of Common Stock In Connection With Initial Public Offering Net Of Issuance Costs Amount IssuanceOfCommonStockInConnectionWithInitialPublicOfferingNetOfIssuanceCostsAmount	3790504	usd
CY2022	aspi	Issuance Of Common Stock Upon Exercise Of Warrants Amount IssuanceOfCommonStockUponExerciseOfWarrantsAmount	0	usd
CY2022	aspi	Issuance Of Restricted Shares Amount IssuanceOfRestrictedSharesAmount	0	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	1999313	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	236307	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-4945139	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9817461	usd
CY2023	aspi	Issuance Of Common Stock Net Of Issuance Costs Amount IssuanceOfCommonStockNetOfIssuanceCostsAmount	13566022	usd
CY2023	aspi	Issuance Of Common Stock For Non Cash Issuance Costs Amount IssuanceOfCommonStockForNonCashIssuanceCostsAmount	0	usd
CY2023	aspi	Proceeds From Issuance Of Common Stocks ProceedsFromIssuanceOfCommonStocks	228000	usd
CY2023	aspi	Settlement Of Liability With Related Parties SettlementOfLiabilityWithRelatedParties	626223	usd
CY2023	aspi	Settlement Of Liability With Consultants Amount SettlementOfLiabilityWithConsultantsAmount	776695	usd
CY2023	aspi	Cancellation Of Common Stock Received In Exchange For Issuance Of Convertible Preferred Stock In Subsidiary Amount CancellationOfCommonStockReceivedInExchangeForIssuanceOfConvertiblePreferredStockInSubsidiaryAmount	0	usd
CY2023	aspi	Issuance Of Restricted Shares Amount IssuanceOfRestrictedSharesAmount	0	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	8743799	usd
CY2023	us-gaap	Noncontrolling Interest Decrease From Deconsolidation NoncontrollingInterestDecreaseFromDeconsolidation	721548	usd
CY2023	aspi	Acquisition Of Pet Labs AcquisitionOfPetLabs	1821021	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1176012	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-16294126	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	18830631	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-16294126	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-4945139	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	44649	usd
CY2022	us-gaap	Depreciation Depreciation	0	usd
CY2023	us-gaap	Depreciation Depreciation	37433	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	8743799	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1999313	usd
CY2023	aspi	Issuance Of Common Stock To Consultant IssuanceOfCommonStockToConsultant	669700	usd
CY2022	aspi	Issuance Of Common Stock To Consultant IssuanceOfCommonStockToConsultant	50000	usd
CY2023	aspi	Change In Fair Value Of Shares Liability ChangeInFairValueOfSharesLiability	-194540	usd
CY2022	aspi	Change In Fair Value Of Shares Liability ChangeInFairValueOfSharesLiability	150527	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	104528	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	72570	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	16655	usd
CY2022	aspi	Increase Decrease In Tax Liabilities Current IncreaseDecreaseInTaxLiabilitiesCurrent	0	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-237952	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	546097	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	671924	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	59324	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	146435	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-224598	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	570600	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	873705	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	319048	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-85775	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-37399	usd
CY2023	aspi	Increase Decrease In Tax Liabilities Current IncreaseDecreaseInTaxLiabilitiesCurrent	-22787	usd
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	0	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	882000	usd
CY2022	aspi	Issuance Of Common Stock In Lieu Of Commissions IssuanceOfCommonStockInLieuOfCommissions	0	usd
CY2023	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	104652	usd
CY2022	aspi	Settlement Of Liabilities With Related Party SettlementOfLiabilitiesWithRelatedParty	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5412392	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2939893	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2331343	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4473164	usd
CY2023	us-gaap	Payments To Acquire Business Two Net Of Cash Acquired PaymentsToAcquireBusinessTwoNetOfCashAcquired	121848	usd
CY2023	aspi	Share Liability For Non Cash Issuance Costs ShareLiabilityForNonCashIssuanceCosts	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2453191	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4473164	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14129495	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8119959	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	563473	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1465461	usd
CY2023	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	526282	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	87713	usd
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	usd
CY2023	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	609499	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	9601	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	13046	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13385491	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6641452	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5519908	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-772005	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-867	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	207424	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2389140	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2953721	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7908181	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2389140	usd
CY2023	aspi	Issuance Of Common Stock In Lieu Of Commissions IssuanceOfCommonStockInLieuOfCommissions	75570	usd
CY2022	aspi	Seller Financed Portion Of Investment In Pet Labs Pharmaceuticals SellerFinancedPortionOfInvestmentInPetLabsPharmaceuticals	0	usd
CY2023	aspi	Settlement Of Liabilities With Related Party SettlementOfLiabilitiesWithRelatedParty	626223	usd
CY2022	aspi	Share Liability For Non Cash Issuance Costs ShareLiabilityForNonCashIssuanceCosts	124782	usd
CY2023	aspi	Seller Financed Portion Of Investment In Pet Labs Pharmaceuticals SellerFinancedPortionOfInvestmentInPetLabsPharmaceuticals	1500000	usd
CY2023	aspi	Purchase Of Property And Equipment Included In Accounts Payable PurchaseOfPropertyAndEquipmentIncludedInAccountsPayable	453985	usd
CY2022	aspi	Purchase Of Property And Equipment Included In Accounts Payable PurchaseOfPropertyAndEquipmentIncludedInAccountsPayable	745628	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	70607	usd
CY2022Q4	us-gaap	Share Price SharePrice	4.00
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	3800000	usd
CY2023	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	16294126	usd
CY2022	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	4945139	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7908181	usd
CY2023	aspi	Amount Received AmountReceived	gross proceeds of $20,550,000 received in March 2024 through the issuance of convertible promissory notes
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The Company’s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of the Company’s consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and disclosure in the Company’s consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to stock based compensation and the accounting for the acquisition. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.</p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Cash balances are maintained at U.S. financial institutions and may exceed the Federal Deposit Insurance Corporation (“FDIC”) insurance limit of $250,000 per depositor, per insured bank for each account ownership category. Although the Company currently believes that the financial institutions with whom it does business, will be able to fulfill their commitments to the Company, there is no assurance that those institutions will be able to continue to do so. The Company has not experienced any credit losses associated with its balances in such accounts for the years ended December 31, 2023 and 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Our foreign subsidiaries held cash of approximately $1,963,000 and $38,000 as of December 31, 2023 and 2022, respectively, which is included in cash on the consolidated balance sheets. Our strategic plan does not require the repatriation of foreign cash in order to fund our operations in the U.S., and it is our current intention to indefinitely reinvest our foreign cash outside of the U.S. If we were to repatriate foreign cash to the U.S., we would be required to accrue and pay U.S. taxes in accordance with applicable U.S. tax rules and regulations as a result of the repatriation.</p>
CY2023Q4	us-gaap	Time Deposits At Or Above Fdic Insurance Limit TimeDepositsAtOrAboveFDICInsuranceLimit	250000	usd
CY2023Q4	us-gaap	Common Stock Held By Subsidiary CommonStockHeldBySubsidiary	1963000	usd
CY2022Q4	us-gaap	Common Stock Held By Subsidiary CommonStockHeldBySubsidiary	38000	usd
CY2022Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	140455	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	116200	usd
CY2022	aspi	Addition On Issuance Of Common Stock AdditionOnIssuanceOfCommonStock	174782	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-150527	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	140455	usd
CY2023	aspi	Addition On Issuance Of Common Stock AdditionOnIssuanceOfCommonStock	669700	usd
CY2023	aspi	Hgu hgu	-1004695	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	194540	usd
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0	usd
CY2023Q4	us-gaap	Variable Interest Entity Ownership Percentage VariableInterestEntityOwnershipPercentage	0.51	pure
CY2023Q4	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	443026	usd
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	460165	usd
CY2023Q4	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	433026	usd
CY2023Q4	aspi	R Evenue Deductions REvenueDeductions	-676687	usd
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	216504	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10750546	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8200595	usd
CY2023Q4	us-gaap	Property Plant And Equipment Other Accumulated Depreciation PropertyPlantAndEquipmentOtherAccumulatedDepreciation	37707	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other Accumulated Depreciation PropertyPlantAndEquipmentOtherAccumulatedDepreciation	0	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10712839	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8200595	usd
CY2023	us-gaap	Depreciation Depreciation	37433	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	447295	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	247125	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	845344	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	98875	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	18606	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	15246	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1311245	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	361246	usd
CY2022Q4	us-gaap	Notes And Loans Payable NotesAndLoansPayable	33854	usd
CY2023Q4	us-gaap	Notes And Loans Payable NotesAndLoansPayable	31827	usd
CY2023	aspi	Acquisition Percentage For Pet Labs Pharmaceuticals AcquisitionPercentageForPetLabsPharmaceuticals	0.51	pure
CY2023Q4	srt	Bank Loans BankLoans	609500	usd
CY2023Q4	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	526282	usd
CY2023Q4	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0874	pure
CY2023Q4	us-gaap	Interest Expense Debt InterestExpenseDebt	2249	usd
CY2023Q4	us-gaap	Other Commitment OtherCommitment	1653000	usd
CY2023	us-gaap	Loss On Contracts LossOnContracts	6800000	usd
CY2022Q4	us-gaap	Other Commitment OtherCommitment	7233000	usd
CY2021Q4	us-gaap	Other Commitment OtherCommitment	1800000	usd
CY2023	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	6050000	usd
CY2023Q2	us-gaap	Loss Contingency Receivable Proceeds LossContingencyReceivableProceeds	626223	usd
CY2023	us-gaap	Legal Fees LegalFees	78304	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	121312	usd
CY2023Q4	aspi	Short Term Operating Lease Future Lease Payments ShortTermOperatingLeaseFutureLeasePayments	37263	usd
CY2022Q1	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	100000	usd
CY2022Q1	aspi	Royalty Percentage On Sale Of Products RoyaltyPercentageOnSaleOfProducts	0.10	pure
CY2022Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6000000	zar
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	354000	usd
CY2023Q2	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	626223	usd
CY2023Q4	aspi	Business Combination Consideration Transferred Cash And Equivalents BusinessCombinationConsiderationTransferredCashAndEquivalents	500000	usd
CY2023Q4	us-gaap	Business Combination Consideration Transferred Other1 BusinessCombinationConsiderationTransferredOther1	1395348	usd
CY2023Q4	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	1895348	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables	378152	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	460165	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther	184457	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	821926	usd
CY2023Q4	aspi	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Right Of Use Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets	592304	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Financial Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities	1248699	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Capital Lease Obligation BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation	677163	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	511142	usd
CY2023Q4	us-gaap	Goodwill Goodwill	3205227	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	1895348	usd
CY2023Q4	us-gaap	Goodwill Goodwill	3205227	usd
CY2023Q4	aspi	Translation Adjustment TranslationAdjustment	61876	usd
CY2023Q4	us-gaap	Goodwill Goodwill	3267103	usd
CY2023	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	3614776	usd
CY2022	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	3065098	usd
CY2023	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-15783485	usd
CY2022	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-4291993	usd
CY2023	aspi	Business Acquisition Pro Forma Earnings Per Share BusinessAcquisitionProFormaEarningsPerShare	-0.48
CY2022	aspi	Business Acquisition Pro Forma Earnings Per Share BusinessAcquisitionProFormaEarningsPerShare	-0.16
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48923276	shares
CY2022	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1559780	shares
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3119560	usd
CY2022	aspi	Payments From Stock Issuance Costs PaymentsFromStockIssuanceCosts	255965	usd
CY2022	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	120491	shares
CY2022Q4	aspi	Fair Value Of Shares Issue FairValueOfSharesIssue	240982	usd
CY2023	aspi	Cash Director Fees CashDirectorFees	45000	usd
CY2022Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	140455	usd
CY2023Q4	aspi	New Share Liabilities NewShareLiabilities	669700	usd
CY2023Q4	aspi	Market Adjustment MarketAdjustment	194540	usd
CY2023Q4	us-gaap	Settlement Liabilities Current SettlementLiabilitiesCurrent	1004695	usd
CY2023Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	0	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.603	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0344	pure
CY2023	aspi	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm	P5Y6M
CY2023	aspi	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedDividendRate	0	pure
CY2022Q4	aspi	Warrants To Purchase Common Stock WarrantsToPurchaseCommonStock	0	shares
CY2023Q4	aspi	Shares Of Common Stock Equivalents SharesOfCommonStockEquivalents	10641262	shares
CY2022Q4	aspi	Shares Of Common Stock Equivalents SharesOfCommonStockEquivalents	9901000	shares
CY2021Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	6000000	shares
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	5000000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	400000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.25
CY2022	aspi	Weighted Average Remaining Contractual Term In Years Beginning WeightedAverageRemainingContractualTermInYearsBeginning	P9Y9M18D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	700000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2751000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.00
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	250000	usd
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.25
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2901000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.91
CY2022	aspi	Weighted Average Remaining Contractual Term In Years Ending WeightedAverageRemainingContractualTermInYearsEnding	P9Y4M24D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	199500	usd
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	135000	usd
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.00
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2766000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.91
CY2023	aspi	Weighted Average Remaining Contractual Term In Years Ending WeightedAverageRemainingContractualTermInYearsEnding	P8Y4M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	231000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1662450	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.88
CY2023	aspi	Weighted Average Remaining Contractual Term In Years Exercisable WeightedAverageRemainingContractualTermInYearsExercisable	P8Y3M18D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	172545	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2766000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.91
CY2023	aspi	Weighted Average Remaining Contractual Term In Years Vested Or Expected To Vest WeightedAverageRemainingContractualTermInYearsVestedOrExpectedToVest	P8Y4M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	231000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2751000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.00
CY2022	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	288000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.18
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	2100000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.25
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	5250000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.24
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	350000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	1.00
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	7000000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.75
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	1756750	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.52
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	4267564	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	1.84
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	4489186	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.42
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8743799	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1999313	usd
CY2023	aspi	Net Loss NetLoss	-16286234	usd
CY2022	aspi	Net Loss NetLoss	-4945139	usd
CY2023	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	33066708	shares
CY2022	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	26793745	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.49
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2766000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2901000	shares
CY2023Q4	aspi	Restricted Stock RestrictedStock	4489186	shares
CY2022Q4	aspi	Restricted Stock RestrictedStock	7000000	shares
CY2023Q4	aspi	Warrants To Purchase Common Stock WarrantsToPurchaseCommonStock	3386076	shares
CY2023	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-16300259	usd
CY2022	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-4945139	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2023	aspi	Earnings In Jurisdictions Taxed At Rates Different From The Statutory Us Federal Tax Rate EarningsInJurisdictionsTaxedAtRatesDifferentFromTheStatutoryUSFederalTaxRate	-0.0058	pure
CY2022	aspi	Earnings In Jurisdictions Taxed At Rates Different From The Statutory Us Federal Tax Rate EarningsInJurisdictionsTaxedAtRatesDifferentFromTheStatutoryUSFederalTaxRate	-0.0589	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.1119	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0	pure
CY2023	aspi	Permanent Differences Income Tax Rate PermanentDifferencesIncomeTaxRate	0.0024	pure
CY2022	aspi	Permanent Differences Income Tax Rate PermanentDifferencesIncomeTaxRate	0.0064	pure
CY2023	aspi	Other Statutory Rate OtherStatutoryRate	-0.0244	pure
CY2022	aspi	Other Statutory Rate OtherStatutoryRate	0.0298	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.0700	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1873	pure
CY2023	aspi	Effectiveincometaxrateincome Tax Expense EffectiveincometaxrateincomeTaxExpense	0.0003	pure
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	2321339	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	496751	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	31622	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	50289	usd
CY2023Q4	us-gaap	Deferred Compensation Plan Assets DeferredCompensationPlanAssets	3644	usd
CY2022Q4	us-gaap	Deferred Compensation Plan Assets DeferredCompensationPlanAssets	418019	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	12647	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	0	usd
CY2023Q4	aspi	Deferredtaxassetstaxdeferredright Of Use Lease Liability DeferredtaxassetstaxdeferredrightOfUseLeaseLiability	276134	usd
CY2022Q4	aspi	Deferredtaxassetstaxdeferredright Of Use Lease Liability DeferredtaxassetstaxdeferredrightOfUseLeaseLiability	243113	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2645386	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1208172	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-6133	usd
CY2023	us-gaap	Real Estate Owned Valuation Allowance Valuation Increase RealEstateOwnedValuationAllowanceValuationIncrease	1182177	usd
CY2022	us-gaap	Real Estate Owned Valuation Allowance Valuation Increase RealEstateOwnedValuationAllowanceValuationIncrease	926104	usd

Files In Submission

Name	View Source	Status
0001477932-24-001964-index-headers.html	Edgar Link	pending
0001477932-24-001964-index.html	Edgar Link	pending
0001477932-24-001964.txt	Edgar Link	pending
0001477932-24-001964-xbrl.zip	Edgar Link	pending
aspi-20231231.xsd	Edgar Link	pending
aspi_10k.htm	Edgar Link	pending
aspi_10kimg1.jpg	Edgar Link	pending
aspi_10kimg2.jpg	Edgar Link	pending
aspi_10kimg3.jpg	Edgar Link	pending
aspi_ex211.htm	Edgar Link	pending
aspi_ex231.htm	Edgar Link	pending
aspi_ex311.htm	Edgar Link	pending
aspi_ex312.htm	Edgar Link	pending
aspi_ex32.htm	Edgar Link	pending
aspi_ex321.htm	Edgar Link	pending
aspi_ex41.htm	Edgar Link	pending
aspi_ex971.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
aspi-20231231_cal.xml	Edgar Link	unprocessable
aspi-20231231_def.xml	Edgar Link	unprocessable
aspi-20231231_lab.xml	Edgar Link	unprocessable
aspi-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
aspi_10k_htm.xml	Edgar Link	completed
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ASPI
ASP Isotopes Inc. Stock $aspi

2024 Q2 Form 10-K Financial Statement

#000147793224001964 Filed on April 10, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ASPI ASP Isotopes Inc. Stock $aspi

2024 Q2 Form 10-K Financial Statement

#000147793224001964 Filed on April 10, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ASPI
ASP Isotopes Inc. Stock $aspi